E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers : Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 26, 2022
August 26, 2022
c6214e5a-c9e4-4ba4-9685-598dee7a9985
Related Documents
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R3) Guidance for Industry
Guidance DocumentJune 28, 2017Center for Drug Evaluation and Research
General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry
Guidance DocumentJuly 27, 2022Center for Drug Evaluation and Research
E2C(R2) Periodic Benefit-Risk Evaluation Report – Questions and Answers
Guidance DocumentJuly 19, 2016Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.